EpiVax Oncology is preparing to enter into a Phase 1b clinical trial in bladder cancer in 2020 with EO-PCV-001: a neo-epitope, formulated peptide based, personalized therapeutic vaccine.

Other tumors under consideration for Phase 1b studies include colorectal, lung, head & neck, melanoma, renal, pancreas and glioblastoma.

Phase I


Phase 2
ANCER™: Superior Neo-Epitope Discovery Process

© Copyright Epivax Oncology 2019